123 related articles for article (PubMed ID: 21669375)
21. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer.
Crawford ED; Black L; Eaddy M; Kruep EJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):162-7. PubMed ID: 20125121
[TBL] [Abstract][Full Text] [Related]
22. [Clinical features of pathologically confirmed metastatic bone tumors--a report of 390 cases].
Xu DL; Zhang XT; Wang GH; Li FB; Hu JY
Ai Zheng; 2005 Nov; 24(11):1404-7. PubMed ID: 16552972
[TBL] [Abstract][Full Text] [Related]
23. Economic burden of metastatic bone disease in the U.S.
Schulman KL; Kohles J
Cancer; 2007 Jun; 109(11):2334-42. PubMed ID: 17450591
[TBL] [Abstract][Full Text] [Related]
24. The systemic treatment of bone metastases.
Houston SJ; Rubens RD
Clin Orthop Relat Res; 1995 Mar; (312):95-104. PubMed ID: 7543393
[TBL] [Abstract][Full Text] [Related]
25. Racial and ethnic variation in health resource use and cost for prostate cancer.
Jayadevappa R; Malkowicz SB; Chhatre S; Gallo J; Schwartz JS
BJU Int; 2010 Sep; 106(6):801-8. PubMed ID: 20151963
[TBL] [Abstract][Full Text] [Related]
26. Assessing the economic burden of breast cancer in a US managed care population.
Barron JJ; Quimbo R; Nikam PT; Amonkar MM
Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
[TBL] [Abstract][Full Text] [Related]
27. Costs associated with resource utilization during the palliative phase of care: a Canadian perspective.
Dumont S; Jacobs P; Fassbender K; Anderson D; Turcotte V; Harel F
Palliat Med; 2009 Dec; 23(8):708-17. PubMed ID: 19837702
[TBL] [Abstract][Full Text] [Related]
28. Bone metastases from advanced cancers: clinical implications and treatment options.
Fitch M; Maxwell C; Ryan C; Löthman H; Drudge-Coates L; Costa L
Clin J Oncol Nurs; 2009 Dec; 13(6):701-10. PubMed ID: 19948468
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers.
Waltregny D; Bellahcène A; de Leval X; Florkin B; Weidle U; Castronovo V
J Bone Miner Res; 2000 May; 15(5):834-43. PubMed ID: 10804012
[TBL] [Abstract][Full Text] [Related]
30. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
31. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
[TBL] [Abstract][Full Text] [Related]
32. Higher costs may justify prophylaxis in prostate and lung cancer patients with bone metastases.
J Support Oncol; 2004; 2(5):456. PubMed ID: 15524079
[No Abstract] [Full Text] [Related]
33. Economic analysis of psychosocial group therapy in women with metastatic breast cancer.
Lemieux J; Topp A; Chappell H; Ennis M; Goodwin PJ
Breast Cancer Res Treat; 2006 Nov; 100(2):183-90. PubMed ID: 16773438
[TBL] [Abstract][Full Text] [Related]
34. Cumulative cost pattern comparison of prostate cancer treatments.
Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
[TBL] [Abstract][Full Text] [Related]
35. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.
Velde NV; Wu EQ; Guo A; Lu M; Yu AP; Sharma H; Liu J; Fan CP; Shi L
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):79-84. PubMed ID: 21173792
[TBL] [Abstract][Full Text] [Related]
36. [Results of the COPD health care costs study. COPD in Germany--unrecognized and cost intensive].
Krankenpfl J; 2003; 41(7-9):158-61. PubMed ID: 14705523
[No Abstract] [Full Text] [Related]
37. Resource use and costs associated with different states of breast cancer.
Lidgren M; Wilking N; Jönsson B; Rehnberg C
Int J Technol Assess Health Care; 2007; 23(2):223-31. PubMed ID: 17493308
[TBL] [Abstract][Full Text] [Related]
38. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer.
Yong C; Onukwugha E; Mullins CD
Curr Opin Oncol; 2014 May; 26(3):274-83. PubMed ID: 24626126
[TBL] [Abstract][Full Text] [Related]
39. Cost of care for elderly cancer patients in the United States.
Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
[TBL] [Abstract][Full Text] [Related]
40. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
